Ruxolitinib: evolution or revolution in treatment of patients with polycythemia vera?

被引：1
|
作者：
Beauverd, Yan [1 ]
McLornan, Donal P. [1 ,2 ]
Radia, Deepti H. [1 ]
Harrison, Claire N. [1 ]
机构：
[1] Guys & St Thomas NHS Fdn Trust, Dept Hematol, London, England
[2] Kings Coll Hosp NHS Fdn Trust, Dept Hematol Med, London, England
来源：
FUTURE ONCOLOGY | 2016年 / 12卷 / 06期
关键词：
myeloproliferative neoplasms; outcomes; polycythemia vera; ruxolitinib; treatment; ESSENTIAL THROMBOCYTHEMIA; JAK INHIBITION; PRIMARY MYELOFIBROSIS; CELL-FUNCTION; LOW TOXICITY; HYDROXYUREA; SAFETY; HYDROXYCARBAMIDE; PHARMACOKINETICS; INTOLERANCE;
D O I：
10.2217/fon-2015-0023
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Current treatments for polycythemia vera have remained unchanged for decades with phlebotomy, hydroxycarbamide (also named hydroxyurea) and to a lesser extent interferon being the cornerstones in our therapeutic armamentarium. However, some patients do not respond to, or indeed experience significant side effects to, these current agents and development of alternative therapeutic options is required. Ruxolitinib, a potent JAK1/2 inhibitor, initially approved for myelofibrosis, was recently approved for patients with polycythemia vera refractory or intolerant to hydroxycarbamide. In this article, we review the currently available efficacy and safety data.
引用
收藏
页码：739 / 749
页数：11
相关论文
共 50 条
  • [41] SECOND NEOPLASMS IN DIAGNOSTIC PATIENTS OF POLYCYTHEMIA VERA (PV) OR MIELOFIBROSIS (MF) TREATED WITH RUXOLITINIB
    Sagues Serrano, M.
    Osca Gelis, G.
    Lopez Brunso, M.
    Gonzalez Montes, Y.
    Buch Villa, J.
    Diaz Santa, J.
    Coll Jorda, R.
    Cruz Garcia, D.
    Carvajal Nazly, Santos Y.
    Lloveras Guelque, N.
    Kelleher, N.
    Roncero Vidal, J. M.
    Blanco Blanco, A. B.
    Mostacedo Marasovic, S. Z.
    Bustins Tarrats, A.
    Serrando Querol, M.
    Jimenez Romero, O.
    Tuset Andujar, E.
    Gallardo Giralt, D.
    HAEMATOLOGICA, 2019, 104 : 310 - 311
  • [42] USE OF RUXOLITINIB IN PATIENTS DIAGNOSED WITH POLYCYTHEMIA VERA (PV): EXPERIENCE OF THE CATALAN INSTITUTE OF ONCOLOGY
    Sagues Serrano, M.
    Osca Gelis, G.
    Estrada, N.
    Vallansot, R.
    Boque Genovard, C.
    Lopez Brunso, M.
    Buch Villa, J.
    Diaz Santa, J.
    Fernandez, A.
    Guerra Prio, S.
    Marull Arnall, A.
    Tejerina Fontaina, P.
    Mateu Esquerda, G.
    Moret Puig, C.
    Quinones Roces, M. T.
    Llopis Puigmarti, M. F.
    Zamora Plana, L.
    Xicoy Cirici, B.
    HAEMATOLOGICA, 2019, 104 : 171 - 171
  • [43] Treatment of polycythemia vera
    Barbui, T
    Finazzi, G
    HAEMATOLOGICA, 1998, 83 (02) : 143 - 149
  • [44] TREATMENT OF POLYCYTHEMIA VERA
    WASSERMAN, LR
    GILBERT, HS
    MEDICAL CLINICS OF NORTH AMERICA, 1966, 50 (06) : 1501 - +
  • [45] COMPLETE HEMATOLOGIC CONTROL WITH RUXOLITINIB IN PATIENTS WITH POLYCYTHEMIA VERA (PV) RESISTANT TO OR INTOLERANT OF HYDROXYUREA
    Harrison, C. N.
    Masszi, T.
    Zachee, P.
    Pane, F.
    Vannucchi, A. M.
    Verstovsek, S.
    Jones, M. M.
    Hunter, D. S.
    He, S.
    Li, J.
    Khan, M.
    Habr, D.
    Kiladjian, J. -J.
    HAEMATOLOGICA, 2015, 100 : 541 - 542
  • [46] Treatment of polycythemia vera
    Silver, Richard T.
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2006, 32 (04): : 437 - 442
  • [47] A Real-Life Turkish Experience of Ruxolitinib in Polycythemia Vera
    Serin, Istemi
    Dogu, Mehmet Hilmi
    Ekinci, Omer
    Cagliyan, Gulsum Akgun
    Basturk, Abdulkadir
    Aras, Merih Reis
    Demircioglu, Sinan
    Turgut, Burhan
    Merter, Mustafa
    Hacioglu, Sibel Kabukcu
    Bagci, Metin
    Albayrak, Murat
    Korkmaz, Serdal
    Erkurt, Mehmet Ali
    Dal, Mehmet Sinan
    Dursun, Fadime Ersoy
    Tombak, Anil
    Aydogdu, Ismet
    Ulas, Turgay
    Altuntas, Fevzi
    ISTANBUL MEDICAL JOURNAL, 2023, 24 (02): : 120 - 125
  • [48] RUXOLITINIB IN POLYCYTHEMIA VERA: INDICATIONS AND EFFICACY IN REAL CLINICAL PRACTICE
    Garrote, M.
    Angona, A.
    Magro, E.
    Perez Encinas, M.
    Mata, M., I
    Ferrer Marin, F.
    Garcia Gutierrez, V
    Sagues, M.
    Murillo, I
    Hernandez Boluda, J. C.
    Alvarez Larran, A.
    HAEMATOLOGICA, 2019, 104 : 64 - 64
  • [49] Treatment with Ruxolitinib (INCB018424) Induced Changes of Microrna Expression in Granulocytes of Patients with Polycythemia Vera and Essential Thrombocythemia
    Guglielmelli, Paola
    Pieri, Lisa
    Tagliarico, Enrico
    Zini, Roberta
    Norfo, Ruggiero
    Bosi, Alberto
    Vaddi, Kris
    Burn, Timothy
    Contel, Nancy
    Verstovsek, Srdan
    Manfredini, Rossella
    Vannucchi, Alessandro M.
    BLOOD, 2011, 118 (21) : 1646 - 1647
  • [50] RUXOLITINIB PROVIDES CONSISTENT HEMATOCRIT CONTROL IN PATIENTS WITH POLYCYTHEMIA VERA (PV) RESISTANT TO OR INTOLERANT OF HYDROXYUREA
    Griesshammer, M.
    Passamonti, F.
    Durrant, S.
    Kiladjian, J. -J.
    Verstovsek, S.
    Jones, M. M.
    Hunter, D. S.
    He, S.
    Urva, S.
    Li, J.
    Khan, M.
    Habr, D.
    Vannucchi, A. M.
    HAEMATOLOGICA, 2015, 100 : 262 - 263
12345